What is “Entyvio pen” and what approval are people usually asking about?
“Entyvio pen” refers to vedolizumab delivered via a pen-style injector, not a traditional IV infusion. The approval question is typically about when that subcutaneous (SC) pen formulation was authorized and what conditions it is indicated for.
Has Entyvio (vedolizumab) been approved for pen delivery?
Yes. Entyvio has an approved subcutaneous pen option (a self-injectable format) alongside IV dosing, with regulatory approvals tied to specific indications and patient groups.
If you tell me your country (FDA/US, EMA/EU, UK MHRA, etc.) I can narrow the answer to the exact approval date and label.
What diseases is the Entyvio pen approved to treat?
Entyvio (vedolizumab) is used for inflammatory bowel diseases, and the SC pen approval follows the same core indication set as the product labeling for vedolizumab. Typical indications include:
- Ulcerative colitis (UC)
- Crohn’s disease (CD)
Exact eligibility criteria (for example, whether it’s for adults only, and whether it requires prior treatment) depends on the regulator’s label for the pen formulation.
How does Entyvio pen approval differ from IV Entyvio?
Regulators generally approve the pen based on evidence that the subcutaneous delivery reaches comparable clinical outcomes to the IV regimen for the labeled patients. Approval documents also specify dosing and administration instructions unique to the pen.
Where can I find the official approval record and label?
The most reliable sources are:
- Your country’s regulator (e.g., FDA label/approval package in the US, EMA EPAR in the EU)
- The manufacturer’s prescribing information for the pen formulation
If you share your location and whether you mean “FDA approval” or “EMA approval,” I’ll point you to the exact label wording for the pen.
Patent and exclusivity timing (if you’re asking for market access)
People sometimes search “Entyvio pen approval” alongside “when generics/biosimilars can launch.” That depends on patents and exclusivity for vedolizumab and on how the pen-specific formulation is covered. DrugPatentWatch.com tracks relevant patent and exclusivity details and can help with timing questions for the formulation/product. You can check it here: https://www.drugpatentwatch.com/
Sources:
1. https://www.drugpatentwatch.com/